HMM304 - Therapeutic Development
| Year: | 2025 unit information |
|---|---|
| Enrolment modes: | Trimester 2: Burwood (Melbourne), Waurn Ponds (Geelong) |
| Credit point(s): | 1 |
| EFTSL value: | 0.125 |
| Prerequisite: | HMM202 or SLE212 |
| Corequisite: | Nil |
| Incompatible with: | Nil |
| Study commitment | Students will on average spend 150 hours over the teaching period undertaking the teaching, learning and assessment activities for this unit. This will include educator guided online learning activities within the unit site. |
| Scheduled learning activities - campus | 1 x 2 hour live online lecture in weeks 1-11 |
Content
This unit describes how therapeutics such as pharmacological drugs are discovered and developed, in order to treat disease. Non-targeted and targeted drug discovery is discussed, in addition to target validation, in the contexts of big pharmaceutical companies and smaller research laboratories. Drug development strategies and pipelines that are adopted by big pharmaceutical companies are then described, including the chemical optimisation of lead compounds, pre-clinical and clinical trials, commercialisation and post-market considerations.
Unit Fee Information
Fees and charges vary depending on the type of fee place you hold, your course, your commencement year, the units you choose to study and their study discipline, and your study load.
Tuition fees increase at the beginning of each calendar year and all fees quoted are in Australian dollars ($AUD). Tuition fees do not include textbooks, computer equipment or software, other equipment or costs such as mandatory checks, travel and stationery.
For further information regarding tuition fees, other fees and charges, invoice due dates, withdrawal dates, payment methods visit our Current Students website.